Alzheimer Neuroinflammation Model
Tbeta4-derived peptides alleviated neuroinflammation and neurite atrophy, improved memory in 5xFAD Alzheimer mice.
[1]A synthetic peptide corresponding to the 7-amino-acid active region of the full 43-amino-acid Thymosin beta-4 protein, specifically the actin-binding sequence. Full-length Tbeta4 regulates actin polymerization, cytoskeletal dynamics, cell migration, and tissue repair. TB-500 retains the core regenerative activity at lower production cost than full-length Tbeta4.
At a glance
- Type
- Synthetic 7-amino-acid fragment of the 43-amino-acid Thymosin beta-4 protein (the actin-binding sequence)
- Mechanism
- Actin polymerization, cytoskeletal dynamics, cell migration, and tissue repair
- Route
- Injectable; some practitioners inject near the target tissue
- Regulatory
- Investigational; reviewed among unapproved peptide therapies
- WADA
- Banned for competitive athletes
- Stacking
- Pairs naturally with BPC-157
What the research supports
TB-500's evidence base spans wound healing, neuroinflammation, corneal repair, and diabetic wound applications with recent engineering advances.
Engineered Tandem Corneal Repair
Engineered tandem thymosin peptide promoted superior corneal wound healing versus monomer.
[2]Diabetic Wound Microneedle Delivery
TB4-engineered extracellular vesicles delivered via microneedle patches rescued cellular senescence and accelerated diabetic wound healing.
[3]Musculoskeletal Peptide Safety Review
Reviewed alongside other unapproved peptide therapies for musculoskeletal injuries and athletic performance.
[4]Summary of key findings
Actin-Driven Tissue Repair
Cytoskeletal remodeling promotes cell migration and angiogenesis at injury sites.
Pairs Naturally with BPC-157
Complementary mechanisms in tendon, ligament, and muscle injury protocols.
Expanding Application Space
Recent 2025 work added corneal, diabetic wound, and CNS neuroinflammation indications.
Cancer History is a Red Flag
Pro-angiogenic and pro-migratory effects are mechanistically concerning in active or recent malignancy.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Loading and Maintenance
- Loading: 2 to 2.5 mg, 1 to 2 times weekly for 4 to 6 weeks. Maintenance: 2 to 2.5 mg every 2 to 4 weeks.
- Localized Injection
- Some practitioners inject near the target tissue for site-specific effect.
- BPC-157 Stacking
- Frequently combined with BPC-157 in tissue repair protocols; complementary angiogenesis and migration mechanisms.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| TB-500 5 mg / 1 mL | 2.5 to 5 mg | 50 to 100 units | Twice per week | 0.05 mg per unit. Works in synergy with BPC-157. |
| TB-500 10 mg / 1 mL | 2.5 to 5 mg | 25 to 50 units | Twice per week | 0.1 mg per unit. Works in synergy with BPC-157. |
WADA Status: Banned for competitive athletes. Counsel patients explicitly.
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
TB-500 is one of the most widely used regenerative peptides in athletic and rehabilitative practice, with mechanism centered on actin-driven cell migration and tissue repair. It pairs naturally with BPC-157, with TB-500 driving cell migration and angiogenesis and BPC-157 driving angiogenesis and tissue protection.
Recent 2025 work expanded the application space significantly: engineered tandem peptides improved corneal wound healing, TB4-loaded extracellular vesicles reversed cellular senescence in diabetic wounds, and neuroinflammation data opened a CNS angle. Cancer history is a relative red flag. Banned by WADA. Frame as investigational despite the deep preclinical evidence base.
Tendon and Muscle Repair
Actin-driven cell migration for connective tissue recovery.
Angiogenesis
Pro-vascular signaling at sites of injury.
Anti-Inflammatory
M1 microglial polarization suppression and cytokine modulation.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Ou et al., 2025 Tbeta4-derived peptides for Alzheimer neuroinflammation
- 2Nguyen et al., 2025 Engineered tandem thymosin peptide for corneal wound healing
- 3Ding et al., 2025 TB4-engineered ADSC EVs in diabetic wound healing
- 4Mendias and Awan, 2026 Peptide therapies for musculoskeletal injuries safety review
- 5Rahman et al., 2026 Therapeutic Peptides in Orthopaedics
Regulatory status, cautions and contraindications
Contraindications and WADA Status
Active or recent malignancy: relative contraindication due to pro-angiogenic activity. Banned by WADA for competitive athletes.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.